Actual Medicinal Product (AMP) Zyloric 300mg tablets (Stephar (U.K.) Ltd)
Stability Information
(Some stability information inherited from generic)
- Stability
-
There are concerns about stability and/or there is a lack of stability data available. These medicines can theoretically be used in MCAs, although use is likely to be off-label. Mitigation measures may need to be considered. Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.
- Notes
-
Manufacturer recommends storing in original container. Protect from light. Anecdotal reports of use in MCAs (low quality evidence).
- Provenance
-
This recommendation is based on the products Zyloric 300mg tablets (Aspen) and Allopurinol 300mg (Ipca Laboratories Ltd) and Allopurinol 200mg tablets (Aspire Pharma).
- Generic
- Allopurinol
- Formulation
- Allopurinol 300mg tablets
-
Allopurinol
-
Allopurinol 300mg tablets
-
Zyloric 300mg tablets (Stephar (U.K.) Ltd)
-
-